Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem Industries has filed a quarterly nil deviation statement for the quarter ended June 30, 2025, confirming no deviation in the use of funds raised through a preferential issue. The company raised Rs 25 crore on April 15, 2025, got listed on BSE on June 25, 2025, and trading commenced on July 14, 2025. The entire Rs 25 crore has been fully utilised by June 30, 2025 for the stated purpose of business expansion and general business purposes. The audit committee and auditors have not raised any comments, and no monitoring agency was required. The company (formerly known as Sun Techno Overseas Limited) confirms that the funds have been used exactly as originally disclosed to shareholders.
This is a routine regulatory compliance filing with no negative implications for shareholders. Full and on-track utilisation of the Rs 25 crore raised shows the company is following through on its stated expansion plans, which is a mildly positive signal for investor confidence.